Encapsulation of an antitumor drug with subsequent controlled release and an extended half-life helps to reduce the toxic effect of TMZ on healthy tissues, protects temozolomide from premature physiological degradation due to MGMT, and delivers it directly to tumor cells. Here, MGMT is linked to neoplasm.